Noxafil
Noxafil is a medicine authorised by Swissmedic under authorisation number 57843. The authorisation holder is MSD Merck Sharp & Dohme AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 02 March 2007 and the authorisation is valid without a time limit. ATC code J02AC04 places the medicine in the group Antimycotics for systemic use.
| Authorisation number | 57843 |
|---|---|
| Name | Noxafil |
| Full name | Noxafil, Suspension zum Einnehmen |
| Authorisation holder | MSD Merck Sharp & Dohme AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | J02AC04 |
| First authorisation | 02 March 2007 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Noxafil, Suspension zum Einnehmen | B | 02 March 2007 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 105 | ml | J02AC04 | 08.06.0. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Noxafil authorised in Switzerland?
Yes. Noxafil is authorised by Swissmedic under authorisation number 57843, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Noxafil have?
Noxafil is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Noxafil?
The authorisation holder is MSD Merck Sharp & Dohme AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.